The rapid adoption of next-generation sequencing (NGS) in clinical molecular laboratories has redefined the practice of cytopathology. Instead of simply being used as a diagnostic tool, cytopathology has evolved into a practice providing important genomic information that guides clinical management. The recent emphasis on maximizing limited-volume cytology samples for ancillary molecular studies, including NGS, requires cytopathologists not only to be more involved in specimen collection and processing techniques but also to be aware of downstream testing and informatics issues. For the integration of molecular informatics into the clinical workflow, it is important to understand the computational components of the NGS workflow by which raw sequence data are transformed into clinically actionable genomic information and to address the challenges of having a robust and sustainable informatics infrastructure for NGS-based testing in a clinical environment. Adapting to needs ranging from specimen procurement to report delivery is crucial for the optimal utilization of cytology specimens to accommodate requests from clinicians to improve patient care. This review presents a broad overview of the various aspects of informatics in the context of NGS-based testing of cytology specimens. Cancer Cytopathol 2017;125:236-44.
INTRODUCTION
The era of personalized medicine has had a dramatic impact on the field of pathology, including cytopathology. With the advent of new molecular tests that can obtain more information from small amounts of tissue, there has been a shift to diagnosing tumors with minimally invasive procedures, including small-needle biopsy and cytology. 1, 2 With these driving forces, cytopathologists have had to re-evaluate the ways in which specimens are procured and processed not only to make a diagnosis but also to accommodate molecular testing requests from oncologists and clinical trials for a variety of biomarkers.
Cytopathologists have always been adept at doing more with less. Being able to recognize cytomorphological features of tumors from limited-volume samples allows them to make diagnoses from fine-needle aspiration (FNA) and exfoliative specimens. 1, 2 Now, more than ever, there is an emphasis on making a diagnosis with minimal material for morphology and immunostains to preserve material for important molecular studies such as assays using next-generation sequencing (NGS). With these demands comes the challenge of applying tests that were originally validated with formalin-fixed, paraffin-embedded (FFPE) surgical pathology tissue to cytological specimens. Although these tests can be readily applied to FFPE cell blocks, using non-formalin-based alternative cytological substrates such as direct smears, cytospin preparations, liquid-based cytology samples, and single cells stored on Fast Technology for Analysis cards can be more challenging because a separate validation needs to be performed to determine the suitability of molecular testing previously performed only with FFPE specimens. [3] [4] [5] [6] [7] [8] Although the variety and versatility of cytological specimen processing offer the cytopathologist morphological clues that aid in diagnoses, 9 the lack of standardized specimen procurement and processing across laboratories poses certain technical challenges for molecular studies.
The pre-analytical variability of cytological specimens arising from various processing techniques, fixatives (eg, alcohol and formalin), and stains (eg, Romanowsky-based, Papanicolaou, and hematoxylin-eosin stains) adds to the complexity of validating molecular assays on these samples. 3, 4, [10] [11] [12] On the other hand, cytological FNA specimens offer important advantages in comparison with histological materials, such as the ability to use rapid onsite evaluation for adequacy assessment and the immediate triaging of material for molecular testing (Table 1) . In general, aspiration cytology specimens provide an excellent source of cellular material for molecular studies because the material is triaged up front in cases with rapid onsite evaluation, samples tend to contain a purer population of tumor cells, and they offer better quality nucleic acids from non-formalin-fixed direct smears. [5] [6] [7] [8] 13 Over time, the cytopathology community has continued to improve processing techniques on the front end to improve molecular testing. Standardized specimen acquisition and processing techniques play a key role in the widespread adoption of alternative cytological specimens (outside of cell blocks) for molecular testing and lead to better utilization of these specimens for clinical decision making and inclusion in clinical trials. The advent of highly multiplexed molecular testing such as NGS has allowed better utilization of limited-volume tissue samples such as FNA specimens because of the low DNA input requirements and the ability to simultaneously screen multiple genes/genomic regions.
10,14-18 NGS technology allows millions of DNA and/or RNA targets to be sequenced in a massively parallel manner; this is more efficient and cost-effective than conventional sequencing methods such as Sanger sequencing. However, incorporating cytological specimens, especially non-FFPE substrates, into a routine clinical NGS workflow is limited by the following: 1) additional validation studies for a variety of substrates, fixatives, and stains that can be resourceintensive; 2) the general reluctance of molecular laboratories to test non-FFPE tissue; 3) the reluctance of cytopathologists to sacrifice direct smears or cytospin preparations from diagnostic archives for molecular testing; 4) the paucity of studies and literature using cytological specimens; and 5) a lack of awareness regarding some of the key advantages offered by cytological specimens for molecular studies. In addition, with the exponential increase in data obtained from NGS analysis of these specimens, there are an increasing number of informatics challenges, including how these data are analyzed, interpreted, reported, and stored. 19, 20 All these factors are changing the field of cytopathology, and as a result, cytopathologists need to be aware of the issues at all stages of the process to adapt to the era of personalized medicine. This review focuses on some of the key concepts of big data and molecular informatics pertaining to cytology specimens.
BIG DATA
With the increasing use of NGS, the massive surge of molecular data presents us with an obtrusive challenge for conventional health care computing resources for data processing and storage. The definition of big data, in contrast to being quantitative, is somewhat nebulous and a moving target. According to the current understanding and experience, big data is a concept that applies to any data set with enough size and complexity that overpowers the capability of conventional computer (informatics) systems (the so-called big data problem). It is, therefore, a relative concept that may confer variable interpretation of the same data set in the continuum of evolving computational power and across business use cases. 21 Although data from a single sample sequence may not be considered big data, the output of NGS-based assays of several hundred to thousands of specimens in routine clinical practice, which is integrated with a multitude of clinical, cytopathological, and laboratory quality-control metadata elements, certainly acquires the characteristics of big data. These characteristics have been described as the 5 V's of big data: volume, velocity, variety, veracity, and value. 22 NGS has been used as a genomics-based research tool for several years. With the rapid decrease in sequencing costs, the introduction of affordable bench-top sequencers, and the recent interest in personalized medicine, NGS is gaining widespread use in the clinical arena with numerous applications in human genetics, 23, 24 cancer, 25 and infectious diseases. 26, 27 The introduction of NGS into clinical laboratories has spurred an exponential need for molecular informatics (or computational pathology). Conventional information systems that were designed to analyze relatively small amounts of structured data lack the capability to analyze large and complex data sets. 28 NGS poses significant pre-analytical, analytical, and post-analytical informatics challenges for the pathology laboratory. 29, 30 This includes high-throughput data analysis, data accuracy, data storage, data interpretation and curation, result visualization, the integration of these large data sets of rapidly evolving (structured and unstructured) data, data transfer and reporting, and data security. One of the biggest challenges facing pathology laboratories aiming to bring on NGS lies in analyzing the massive amounts of clinically relevant molecular data and integrating them into clinical informatics applications such as electronic health records (EHRs) and laboratory information systems (LISs) for compliance and data-driven clinical decision making.
29,31
DATA RELATED TO WORKFLOW
The workflow of NGS testing involves both wet-bench operations (eg, DNA extraction, library preparation, and sequencing) and dry-bench operations (eg, signal processing, sequence alignment, and variant calling; Fig. 1 ). Both of these processes are tied to data requirements. In a clinical NGS laboratory, the informatics workflow begins in the pre-analytical phase with test ordering and accessioning of the specimen. This involves receipt of the test order along with patient consent for molecular testing. Ideally, such orders should be received electronically and interfaced with the LIS and possibly even the sequencing instrument to avoid the need to manually re-enter data. The next phase of the test process involves library preparation followed by sequencing on an instrument. This generates large amounts of unstructured raw data, which then need to be analyzed with a bioinformatics pipeline. A bioinformatics pipeline is a sequence of defined data analysis steps executed by an array of different software programs and algorithms with the expectation of identifying sequence variants or other genomic alterations of interest from raw sequence data. Some of these processes also involve numerous queries against large public and proprietary databases for variant annotation. Clinically significant data then need to be interpreted and reported with structured formatting of results by a molecular pathologist and transmitted downstream into the EHR. Finally, these large amounts of data need to be archived to be used later for validation studies, data mining, and possibly research. The flow of data related to an NGS workflow is summarized in Table 2 .
DRY-BENCH DATA PROCESSING
Informatics challenges related to dry-bench processing in the clinical molecular laboratory are relatively unique 32, 33 in comparison with other types of testing performed in the pathology laboratory. Dry-bench data analysis encompasses taking raw signal data (optical or electrical) through serial intermediary steps of signal processing, base calling, alignment against a reference genome sequence, prevariant calling optimization, and variant calling. The informatics aspect of such analytical processes comprises the following phases: 1) a primary analysis that involves the generation of sequence reads and associated quality scores from raw sequenced signals (base calling); 2) a secondary analysis that involves demultiplexing, alignment of the sequence reads to a reference sequence, and variant calling; and 3) a tertiary analysis that involves annotation of variant calls, interpretation, and reporting for clinical decision making. 34 Some of the important steps are discussed next.
Sequence Alignment
Platform-specific algorithms generate primary base calls that are assigned a Phred-like quality score (Q score) that reflects the confidence in the validity of the call. The sequences are stored in the FASTQ format. The individual sequences are subsequently aligned against a reference genome (eg, human reference genome GRCh38 from the Genome Reference Consortium) with alignment tools (eg, Burrows-Wheeler Aligner, Bowtie, SOAP2, Maq, and Novoalign [35] [36] [37] [38] . The aligned reads tagged with metadata are stored as sequence alignment map (SAM) or binary form of sequence alignment map (BAM) files in preparation for the next step, variant calling, which identifies any areas of difference between the patient sample and the reference genome.
Variant Calling
A variety of applications are available for identifying variants based on mismatches/gaps in reads in the aligned SAM/BAM files (eg, Genome Analysis Toolkit, VarScan2, Atlas2, MuTect, and SAM tools). [39] [40] [41] [42] The performance of many of these software applications depends largely on the algorithm used, the sequencing platform, the depth of coverage, and the type of variant detected. Several studies have shown low concordance among all the different data analysis pipelines that were tested, particularly with mutations that are present at low frequencies. [43] [44] [45] Therefore, current recommendations suggest using multiple data analysis tools to detect the widest range of variant calls and then using a minimum consensus threshold to identify calls that can be validated. 29 
Variant Assessment
The sequence variants detected are rendered in one of many variant call formats, such as the variant call format (VCF), genomic variant call format (gVCF), or general feature format (GFF3 
INFORMATICS CHALLENGES
The informatics processes for clinical NGS tests are centered on converting signals into data and data into meaningful genomic information and ultimately humanreadable reports for clinically actionable knowledge. Although NGS is being rapidly adopted into the clinical workflow of several molecular laboratories, the clinical informatics domain has mostly been unable to develop at the same rapid pace, and this has created difficulties for these laboratories in scaling up their operations to meet the current clinical demand for NGS testing. As a result, molecular laboratories are struggling to find automated solutions to support paperless workflows, electronic interfacing with existing clinical informatics infrastructure (eg, EHR and LIS), report synthesis, seamless data transmission, and quality assurance. The upstream process of data generation appears to be far less of a bottleneck than the downstream data management, analysis, and integration. 48 Although NGS technology is rapidly evolving, legacy EHR and LIS applications are unable to import, transmit, or store any NGS data. Similarly, many of the NGS platforms are unable to accept, use, or transmit standard electronic transmissions (eg, Health Level 7). Although laboratory-or custom-developed molecular modules may work well initially, they require dedicated information technology (IT) resources for ongoing support. The ideal molecular laboratory information system (M-LIS) should handle incoming and outbound electronic Health Level 7 transactions for ordering and resulting, track the workflow in the NGS laboratory, connect to pipelines for data analytics and interpretation, and provide a mechanism to render structured reports. A unified M-LIS should combine the functionality of a traditional LIS and a laboratory information management system (LIMS). This includes integrating core laboratory operations of computerized order entry, sample tracking, inventory management, and result transmission as well as managing large data sets, billing, and security. Examples of commercial MLISs include the Clinical Genomicist Workspace (PerianDx) and Clarity LIMS (GenoLogics).
DATA STORAGE AND COMPUTATIONAL NEEDS
NGS uses massively parallel sequencing by generating numerous overlapping relatively short DNA fragments (50-400 base pairs) over a specified genomic region (targeted/exome sequencing) or over the entire genome (whole-genome sequencing). Exome sequencing provides genomic information for exonic regions of all annotated genes and results in a raw data file of 10 to 100 GB; the size depends on the sequencing platform and the desired depth of coverage and read lengths. Therefore, for 100 samples, the data storage would be roughly 1.5 TB. On the other hand, whole-genome sequencing provides information on all 6 billion bases (ie, 3000 3 more data), and this results in a raw data file of 200 to 500 GB. For 100 samples, that would translate into 25 TB of data storage. The NGS data analysis pipeline generates sequential intermediary files in addition to the raw sequence files. This adds significantly to the storage requirements for each sample or run.
Most clinical molecular laboratories are not equipped to store such large volumes of data. Clinical genomic data need secure long-term storage with automatic scheduling, redundancy, offsite backup, and disaster-recovery protocols. Unfortunately, there are also no clear guidelines in terms of data storage for clinical laboratories, and the decision on the types of files that are selected for long-term storage depends largely on the IT storage capacity and resources of individual laboratories. Raw data files are extremely large and may consequently be stored only for a limited period of time, whereas intermediate data are smaller and can be stored for the long term for much lower costs. 49 Clinical NGS testing requires high-throughput computational resources and the support of a robust IT infrastructure. Desktop workstations require multicore processors, large quantities of memory, and efficient graphics processing units to allow high-throughput analysis. However, scaling up in such settings often requires high-performance cluster computing or cloud computing. Cluster computing refers to multiple computers (nodes) set up in parallel in a networked environment to provide massive computing power that can be scaled to meet the computational needs of the laboratory. Cloud computing refers to a collection of computing resources, including storage, hardware, and software, that can be rendered on demand in an easily configurable and scalable format. Cloud computing provides clinical laboratories with hardware and software infrastructure without the need of a large capital investment. In-house enterprise data centers or commercial cloud service providers provide cloud storage. However, it is the responsibility of the health care organization and users to ensure that desired cloud computing services are in compliance with regional, state, and national health regulation policies. Private institutional cloud computing is hence more attractive from the perspective of a clinical laboratory; however, the financial and infrastructure resources required may be prohibitory for many institutions.
Many institutions are currently building enterprise data warehouses and are adding genetic mutations to it. This provides the ability to perform data mining and analytics and to use these data sets to build algorithms and determine business trends/intelligence. It is critical to have an infrastructure for data governance (ie, to establish rules for data usage, establish policy, put a data approval process in place, identify stakeholders, establish decision rights, clarify accountabilities, and clarify the value of datarelated projects). However, there is currently a lack of clarity in terms of enterprise data ownership and data governance stewardship. Academic clinical laboratories are increasingly facing the challenges of dealing with enterprise data ownership.
REPORTING RESULTS
The clinical interpretation of NGS data is not trivial. The sheer range of genomic alterations that are detected by NGS requires complex data interpretation in conjunction with the clinical history and tumor type as well as a review of variant data and supporting literature and a comparison of the findings with a curated database. The challenge of interpreting data is frequently complicated by the identification of variants of undetermined significance that are beyond our current understanding of molecular pathways. As the areas of the human genome that are sequenced expand outside known oncogenic hotspots, for instance, the variants that are incidental and of no specific functional impact (passenger mutations) may rapidly outnumber those that are significant. Several Web-based analytics tools are available for variant interpretation and annotation; however, a large portion of these steps remain a manual process that can be timeconsuming, and this also results in variability across institutions and laboratories. Hence, offering clinicians comprehensive reports (Fig. 2) that summarize all of the key results of NGS testing is highly recommended. 50 The molecular pathologist plays a pivotal role in this process. The decision to include therapeutic information (eg, Food and Drug Administration-approved therapy and clinical trials) that matches the tumor genomic profile is a very important component of a comprehensive NGS report. Matching clinical trials appropriate to a patient's tumor is a very challenging task (logistically and informatically); therefore, a manual review of electronically matched clinical trials or therapies by molecular pathologists is crucial for a meaningful clinical report. Several efforts toward the development of informatics solutions for streamlining clinical trial matching and incorporating those results into clinical reports are being actively pursued by noncommercial and commercial entities.
In addition, ethical considerations need to be taken into account for NGS reporting because pathogenic germline variants can be identified as incidental findings during tumor-specific somatic NGS testing. Such situations present us with several challenges that need to be ironed out, such as the requirement for pretest consent and counseling, the clinical utility of reporting potential germline variants, the potential for genetic discrimination based on test results (adverse personal or societal consequences), falsepositive/negative results, and uncertain implications for early interventions that test results may provoke. Although technological barriers are continuing to be reduced, ethical considerations increasingly are becoming the rate-limiting process. The transmission of these results also remains challenging because most clinical information systems are currently not set up to manage NGS data. 52, 53 
CONCLUSION
In conclusion, NGS testing for precision medicine has had a significant impact on the clinical management of patients with solid tumor malignancies. Although major strides in NGS technology have enabled us to test patients for a wide array of genomic alterations with small tissue samples, including cytology FNA specimens, there remain significant informatics challenges for the clinical testing, interpretation, and reporting of these specimens. To sustain the continued rapid growth of molecular diagnostics, laboratories performing clinical NGS testing will need to develop a strategic plan to develop their IT infrastructure and informatics resources to sustain such testing. This includes the ability to handle large, complex data sets, a flexible and scalable IT infrastructure, the ability to support and track an efficient workflow, and Health Insurance Portability and Accountability Act-compliant data-storage and datasharing solutions. To meet these informatics challenges, a multidisciplinary approach including pathologists, bioinformaticians, technical personnel, computer programmers, and IT specialists is necessary. As NGS is increasingly used with small samples for clinical decision making, cytopathologists are likely to play critical roles in this process, such as standardization of the upstream pre-analytical variables related to specimen acquisition and processing, which may help to streamline some of the downstream informatics bottlenecks currently plaguing clinical molecular laboratories.
